Sign in
SGP Stock Price, Chart, Stats & News
SpyGlass Pharma, Inc. Common Stock
Save
628.88M
Market cap
–
Current P/E
–
Forward P/E
SGP chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 38.80% |
Operating margin | 23.62% |
Pretax margin | 28.08% |
Net margin | 26.33% |
Effective tax rate | 6.24% |
ROA | 4.66% |
ROE | 8.21% |
D/E | 0.51x |
Interest coverage ratio | – |
SGP valuation
P/E | – |
P/S | 4.38x |
P/B | 1.34x |
P/CF | 41.72x |
P/FCF | 42.25x |
P/OCF | 41.72x |
PEG | 0.21x |
EV multiple | 23.97x |
About
SpyGlass Pharma, Inc. is an advanced biopharmaceutical company dedicated to developing innovative therapeutic approaches for individuals suffering from chronic eye conditions. Its flagship investigational product, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), is engineered for implantation during standard cataract removal procedures with the aim of reducing elevated intraocular pressure (IOP) in patients afflicted with either open-angle glaucoma (OAG) or ocular hypertension (OHT). Co-founded in January 2019 by Malik Y.
Similar securities
Based on sector and market capitalization
Report issue